How Gene Therapy Works: A Beginner's Guide

Imagine you have a typo in a critical instruction manual, and that typo causes your factory to produce defective parts. Gene therapy is, at its simplest, the medical approach of fixing — or replacing — that faulty instruction at the genetic level. Instead of treating symptoms with lifelong medication, gene therapy aims to address the root cause of genetic disease.

What Is Gene Therapy?

Gene therapy is a medical technique that uses genetic material (DNA or RNA) to treat or prevent disease. Rather than using drugs or surgery, gene therapy works by:

1. Replacing a faulty gene with a working copy
2. Inactivating a malfunctioning gene that's causing problems
3. Introducing a new gene to help fight a disease

The concept is straightforward. The challenge has always been execution: how do you get the right genetic material into the right cells, in the right amount, without harming the patient?

The Delivery Problem

DNA doesn't just walk into cells on its own. You need a vector — a delivery vehicle that carries the therapeutic gene into target cells. This is the central engineering challenge of gene therapy, and it's been the main bottleneck for decades.

Viral Vectors

Viruses are nature's gene delivery experts. They've evolved over billions of years to inject their genetic material into cells. Gene therapists have repurposed this ability by removing the viral genes that cause disease and replacing them with therapeutic genes. The result: a virus that infects cells and delivers beneficial genes instead of harmful ones.

The three most common viral vectors:

Adeno-Associated Virus (AAV)

• Tiny virus that doesn't cause disease in humans
• Delivers genes that persist in cells but mostly don't integrate into chromosomes
• Works well for liver, eye, muscle, and brain
• Limitation: small cargo capacity (~4.7 kb), immune responses with repeated dosing
• Used in: Luxturna (inherited blindness), Zolgensma (spinal muscular atrophy)

Lentivirus

• Derived from HIV (modified to be safe)
• Integrates the therapeutic gene permanently into the cell's chromosomes
• Ideal for cells that divide frequently (like blood stem cells)
• Used in: Casgevy, Lyfgenia (sickle cell disease), CAR-T cell therapies

Adenovirus

• Larger cargo capacity than AAV
• Strong immune response (which can be a feature for vaccines, but a bug for gene therapy)
• Gene expression is temporary
• Used in: Some cancer gene therapies and COVID-19 vaccines (AstraZeneca, J&J)

Non-Viral Delivery

Newer approaches avoid viruses entirely:

Lipid Nanoparticles (LNPs)

• Tiny fat bubbles that encapsulate genetic material
• Made famous by mRNA COVID-19 vaccines (Pfizer, Moderna)
• Now being used for gene editing delivery (e.g., Intellia's NTLA-2001)
• Can be redosed (unlike AAV), but currently mostly target the liver

Electroporation

• Uses electric pulses to temporarily open pores in cell membranes
• Genetic material slips through the pores into the cell
• Works well for ex vivo approaches (editing cells in a dish)

Two Approaches: Ex Vivo vs. In Vivo

Ex Vivo Gene Therapy

"Outside the body" — cells are removed from the patient, genetically modified in the laboratory, and then returned.

The process:

1. Collect target cells (usually blood stem cells via apheresis)
2. Edit or modify the cells in the lab using viral vectors or gene editing tools
3. Destroy the patient's existing stem cells with chemotherapy (myeloablative conditioning)
4. Infuse the modified cells back into the patient
5. Modified cells engraft and produce corrected cells going forward

Examples: Casgevy (sickle cell), CAR-T cell therapies (cancer), Strimvelis (ADA-SCID)

Pros: Precise control over editing, can verify cells before returning them Cons: Invasive, requires chemotherapy conditioning, expensive, only works for accessible cell types

In Vivo Gene Therapy

"Inside the body" — the therapeutic vector is delivered directly to the patient, targeting cells in place.

The process:

1. Package the therapeutic gene in a vector (AAV, LNP, etc.)
2. Administer via injection (intravenous, intramuscular, subretinal, intrathecal, etc.)
3. The vector reaches target cells and delivers the gene
4. Target cells begin producing the therapeutic protein

Examples: Luxturna (eye injection for blindness), Zolgensma (IV for spinal muscular atrophy), Intellia's NTLA-2001 (IV LNP for liver disease)

Pros: Less invasive, can reach organs that can't be removed and edited Cons: Harder to control dosing, potential immune reactions, off-target delivery

Gene Therapy vs. Gene Editing

These terms are related but distinct:

• Gene therapy (traditional): Adds a working copy of a gene — the faulty gene is still there, but the new copy compensates. Like adding a correct page to a manual with a typo.
• Gene editing (CRISPR, base editing, etc.): Fixes the faulty gene itself at its original location. Like finding the typo and correcting it directly.

Modern gene therapy increasingly uses gene editing tools. Casgevy, for example, is technically both — it's a gene therapy (cells are modified and returned) that uses gene editing (CRISPR cuts the BCL11A gene) as its mechanism.

Current Landscape

As of 2026, there are dozens of approved gene therapies worldwide:

• Casgevy — CRISPR-based, for sickle cell disease and beta thalassemia
• Lyfgenia — Lentiviral, for sickle cell disease
• Luxturna — AAV-based, for inherited retinal dystrophy
• Zolgensma — AAV-based, for spinal muscular atrophy
• Hemgenix — AAV-based, for hemophilia B
• Elevidys — AAV-based, for Duchenne muscular dystrophy

Hundreds more are in clinical trials targeting cancer, heart disease, neurological disorders, blood diseases, and rare genetic conditions.

The Cost Question

Gene therapies are among the most expensive treatments in medicine:

• Zolgensma: ~$2.1 million (single dose)
• Hemgenix: ~$3.5 million (single dose)
• Casgevy: ~$2.2 million (single treatment course)

The argument for these prices is that a one-time cure replaces a lifetime of treatment. A sickle cell patient might otherwise spend $1–2 million over their lifetime on blood transfusions, hospitalizations, and pain management. But the upfront cost creates massive access barriers, particularly in low-income countries where genetic diseases like sickle cell are most prevalent.

Key Takeaways

• Gene therapy treats disease by delivering genetic material into cells to replace, inactivate, or add genes
• Viral vectors (AAV, lentivirus) and non-viral methods (LNPs, electroporation) are the main delivery vehicles
• Ex vivo therapy edits cells outside the body; in vivo therapy delivers genes directly into the patient
• Gene therapy and gene editing are converging — modern therapies increasingly use both
• Dozens of gene therapies are now approved, with hundreds more in clinical trials
• Cost remains the biggest barrier to access

Now that you understand the fundamentals of gene therapy, let's explore one of its most remarkable applications: CAR-T cell therapy, where a patient's own immune cells are genetically reprogrammed to fight cancer.